524 related articles for article (PubMed ID: 31195825)
21. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The Chronic Total Occlusion Cohort in the IN.PACT Global Study.
Tepe G; Micari A; Keirse K; Zeller T; Scheinert D; Li P; Schmahl R; Jaff MR;
JACC Cardiovasc Interv; 2019 Mar; 12(5):484-493. PubMed ID: 30846089
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
[TBL] [Abstract][Full Text] [Related]
23. 2-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
Micari A; Nerla R; Vadalà G; Castriota F; Grattoni C; Liso A; Russo P; Pantaleo P; Roscitano G; Cremonesi A
JACC Cardiovasc Interv; 2017 Apr; 10(7):728-734. PubMed ID: 28385412
[TBL] [Abstract][Full Text] [Related]
24. Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention.
Krishnan P; Farhan S; Schneider P; Kamran H; Iida O; Brodmann M; Micari A; Sachar R; Urasawa K; Scheinert D; Ando K; Tarricone A; Doros G; Tepe G; Yokoi H; Laird J; Zeller T
J Am Coll Cardiol; 2022 Sep; 80(13):1241-1250. PubMed ID: 36137674
[TBL] [Abstract][Full Text] [Related]
25. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial.
Tepe G; Laird J; Schneider P; Brodmann M; Krishnan P; Micari A; Metzger C; Scheinert D; Zeller T; Cohen DJ; Snead DB; Alexander B; Landini M; Jaff MR;
Circulation; 2015 Feb; 131(5):495-502. PubMed ID: 25472980
[TBL] [Abstract][Full Text] [Related]
26. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
[TBL] [Abstract][Full Text] [Related]
27. Total IN.PACT drug-coated balloon initiative reporting pooled imaging and propensity-matched cohorts.
Shishehbor MH; Schneider PA; Zeller T; Razavi MK; Laird JR; Wang H; Tieché C; Parikh SA; Iida O; Jaff MR
J Vasc Surg; 2019 Oct; 70(4):1177-1191.e9. PubMed ID: 31543165
[TBL] [Abstract][Full Text] [Related]
28. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
Bausback Y; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
J Endovasc Ther; 2017 Aug; 24(4):459-467. PubMed ID: 28558502
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes after paclitaxel-coated balloon angioplasty of femoropopliteal arteries in Asian patients of the IN.PACT Global Study.
Ko YG; Choi D; Rha SW; Won JH; Do YS; Lee SW; Menk JS; Kum S
Catheter Cardiovasc Interv; 2022 Dec; 100(7):1273-1283. PubMed ID: 36385562
[TBL] [Abstract][Full Text] [Related]
30. The 24-Month Results of the Lutonix Global SFA Registry: Worldwide Experience With Lutonix Drug-Coated Balloon.
Thieme M; Von Bilderling P; Paetzel C; Karnabatidis D; Perez Delgado J; Lichtenberg M;
JACC Cardiovasc Interv; 2017 Aug; 10(16):1682-1690. PubMed ID: 28780030
[TBL] [Abstract][Full Text] [Related]
31. Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study.
Micari A; Brodmann M; Keirse K; Peeters P; Tepe G; Frost M; Wang H; Zeller T;
JACC Cardiovasc Interv; 2018 May; 11(10):945-953. PubMed ID: 29798770
[TBL] [Abstract][Full Text] [Related]
32. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
Scheinert D; Duda S; Zeller T; Krankenberg H; Ricke J; Bosiers M; Tepe G; Naisbitt S; Rosenfield K
JACC Cardiovasc Interv; 2014 Jan; 7(1):10-9. PubMed ID: 24456716
[TBL] [Abstract][Full Text] [Related]
33. Sex-Related Differences in the Long-Term Outcomes of Patients with Femoropopliteal Arterial Disease Treated with the IN.PACT Drug-Coated Balloon in the IN.PACT SFA Randomized Controlled Trial: A Post Hoc Analysis.
Kohi MP; Brodmann M; Zeller T; Micari A; Baumgartner I; Wang H; Wall B; Razavi MK
J Vasc Interv Radiol; 2020 Sep; 31(9):1410-1418.e10. PubMed ID: 32868016
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel exposure: Long-term safety and effectiveness of a drug-coated balloon for claudication in pooled randomized trials.
Schneider PA; Brodmann M; Mauri L; Laird J; Soga Y; Micari A; Ansel G; Shishehbor MH; Krishnan P; Gao Q; Ouriel K; Zeller T
Catheter Cardiovasc Interv; 2020 Nov; 96(5):1087-1099. PubMed ID: 32830913
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel-Coated Balloon for the Treatment of Infrainguinal Disease: 12-Month Outcomes in the All-Comers Cohort of BIOLUX P-III Global Registry.
Tepe G; Zeller T; Moscovic M; Corpataux JM; Christensen JK; Keirse K; Nano G; Schroeder H; Binkert CA; Brodmann M
J Endovasc Ther; 2020 Apr; 27(2):304-315. PubMed ID: 31989855
[No Abstract] [Full Text] [Related]
36. Long-term safety and efficacy of angioplasty of femoropopliteal artery disease with drug-coated balloons from the AcoArt I trial.
Xu Y; Liu J; Zhang J; Zhuang B; Jia X; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W
J Vasc Surg; 2021 Sep; 74(3):756-762.e3. PubMed ID: 33600928
[TBL] [Abstract][Full Text] [Related]
37. 1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
Micari A; Vadalà G; Castriota F; Liso A; Grattoni C; Russo P; Marchese A; Pantaleo P; Roscitano G; Cesana BM; Cremonesi A
JACC Cardiovasc Interv; 2016 May; 9(9):950-6. PubMed ID: 27151609
[TBL] [Abstract][Full Text] [Related]
38. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery).
Liistro F; Grotti S; Porto I; Angioli P; Ricci L; Ducci K; Falsini G; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
JACC Cardiovasc Interv; 2013 Dec; 6(12):1295-302. PubMed ID: 24239203
[TBL] [Abstract][Full Text] [Related]
39. Comparison of drug-coated balloon angioplasty versus uncoated balloon angioplasty in treatment of total occlusions with severe femoropopliteal lesions: An additional analysis from the AcoArt I study.
Sun G; Liu J; Jia S; Zhang J; Zhuang B; Jia X; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W;
Vascular; 2021 Jun; 29(3):340-349. PubMed ID: 32903168
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Outcomes of the 150 mm Drug-Coated Balloon Cohort from the IN.PACT Global Study.
Brodmann M; Lansink W; Guetl K; Micari A; Menk J; Zeller T
Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1276-1287. PubMed ID: 35864209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
